The discovery of the anti-viral APOBEC3 proteins is regarded as one of the most therapeutically promising breakthroughs in HIV/AIDS molecular virology in recent years. Humans have seven APOBEC3 proteins and at least two, APOBEC3F and APOBEC3G, are known to inhibit the replication of Vif-deficient HIV. HIV pathogenesis is consequently dependent on its Vif protein, which counteracts the APOBEC3 proteins and triggers their degradation. This proposal has three major aims. First, we will test the hypothesis that at least three or more APOBEC3s contribute to HIV restriction in vivo. A combination of methods will be used to identify the minimal set of APOBEC3s required for restriction including gene targeting, short hairpin RNA knockdowns, experiments with APOBEC3-resistant virus isolates and the use of novel APOBEC3 inhibitors. These studies will show definitively which APOBEC3s contribute to HIV restriction in non-permissive T-cell lines and pathogenesis-relevant primary CD4+ T lymphocytes. Second, we will test the hypothesis that APOBEC3 proteins are regulated by phosphorylation. The residues responsible will be identified by a combination of mutagenesis and phospho-peptide mapping. Preliminary studies indicate that APOBEC3G is phosphorylated minimally at three distinct residues. Phosphorylation may function to hard-wire APOBEC3G to signal transduction pathways, allowing for rapid activation of the protein in response to infection. Third, we will test the hypothesis that the APOBEC3 proteins homo- and hetero-oligomerize to form a combinatorial restriction network with a broader range of anti-viral activities exceeding those of individual APOBEC3s. The higher order network will be elucidated and its relevance to restriction evaluated by co-immunoprecipitation, co-encapsidation, single cycle, and spreading infection assays. The interaction domains will be determined by complimentary yeast-based and structure-guided mutagenesis experiments. Taken together, these studies will advance our fundamental understanding of the HIV-relevant human APOBEC3 proteins and facilitate the development of novel HIV/AIDS therapeutics that work by modulating the APOBEC3-Vif pathway.

Public Health Relevance

A detailed molecular understanding of the human APOBEC3 proteins and the host-pathogen conflict that occurs between these and the HIV Vif protein will contribute to the development of novel therapeutics that boost our normal innate immune responses to HIV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
3R56AI064046-06A1S1
Application #
8136830
Study Section
AIDS Molecular and Cellular Biology Study Section (AMCB)
Program Officer
Salzwedel, Karl D
Project Start
2010-09-20
Project End
2011-09-19
Budget Start
2010-09-20
Budget End
2011-09-19
Support Year
6
Fiscal Year
2010
Total Cost
$154,331
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Biochemistry
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Shaban, Nadine M; Shi, Ke; Li, Ming et al. (2016) 1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure. J Mol Biol 428:2307-2316
Shi, Ke; Carpenter, Michael A; Kurahashi, Kayo et al. (2015) Crystal Structure of the DNA Deaminase APOBEC3B Catalytic Domain. J Biol Chem 290:28120-30
Harjes, Stefan; Solomon, William C; Li, Ming et al. (2013) Impact of H216 on the DNA binding and catalytic activities of the HIV restriction factor APOBEC3G. J Virol 87:7008-14
Li, Ming; Shandilya, Shivender M D; Carpenter, Michael A et al. (2012) First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol 7:506-17
Shlyakhtenko, Luda S; Lushnikov, Alexander Y; Li, Ming et al. (2011) Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J Biol Chem 286:3387-95
Refsland, Eric W; Stenglein, Mark D; Shindo, Keisuke et al. (2010) Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 38:4274-84
Shandilya, Shivender M D; Nalam, Madhavi N L; Nalivaika, Ellen A et al. (2010) Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 18:28-38
Stenglein, Mark D; Burns, Michael B; Li, Ming et al. (2010) APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol 17:222-9
Larue, Rebecca S; Lengyel, Joy; Jonsson, Stefan R et al. (2010) Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol 84:8193-201
Sadler, Holly A; Stenglein, Mark D; Harris, Reuben S et al. (2010) APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 84:7396-404

Showing the most recent 10 out of 13 publications